Ultragenyx to Present at H.C. Wainwright BioConnect Healthcare Conference

Rhea-AI Summary

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has announced that CEO Emil D. Kakkis will present at the H.C. Wainwright BioConnect Conference on January 13, 2022, at 7:00 AM ET. The presentation will be available via live and archived webcast on the company's website for 90 days. Ultragenyx focuses on developing therapies for rare and ultra-rare genetic diseases, with a portfolio aimed at addressing conditions with high unmet medical needs. The company emphasizes efficient drug development to deliver urgent therapies to patients.

NOVATO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the H.C. Wainwright BioConnect Conference on Thursday, January 13, 2022 at 7:00 AM ET.

The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contacts
Ultragenyx Pharmaceutical, Inc.
Investors
Rob Anstey
ir@ultragenyx.com

Media
Jeff Blake
415-612-7784
media@ultragenyx.com

FAQ

When is the H.C. Wainwright BioConnect Conference presentation for Ultragenyx (RARE)?

The presentation will take place on January 13, 2022, at 7:00 AM ET.

Where can I watch the Ultragenyx (RARE) BioConnect Conference presentation?

The presentation can be viewed live and in archive on Ultragenyx's website.

What is Ultragenyx Pharmaceutical Inc. (RARE) focused on?

Ultragenyx focuses on developing therapies for serious rare and ultra-rare genetic diseases.

How long will the Ultragenyx (RARE) presentation be available for replay?

The replay of the presentation will be available for 90 days.

Who is presenting for Ultragenyx (RARE) at the conference?

Emil D. Kakkis, M.D., Ph.D., the CEO and President of Ultragenyx, will present.